Characterization of the Patient Profile and Efficacy of Empirical Radioiodine Therapy in Differentiated Thyroid Cancer With Biochemical Evidence Without Identified Iodine-Avid Structural Metastatic Disease

Key Points

• The aim is to assess the efficacy of empirical radioiodine therapy in differentiated thyroid cancer despite the absence of iodine-avid structural metastases.
• Administered radioiodine therapy based on biochemical evidence of metastases.
• Evaluated for iodine-avid metastatic foci.
• Monitored serum thyroglobulin (TG) levels for treatment outcomes.
• 57% of patients had identified metastatic foci that were avid for iodine after therapy.
• Subsequent reduction in serum TG levels indicated potential benefits from treatment.
• Outcomes varied between patients receiving radioiodine therapy and those who did not.